The Supportive Role of NSC328382, a P2X7R Antagonist, in Enhancing the Inhibitory Effect of CRID3 on NLRP3 Inflammasome Activation in Rats with Dextran Sodium Sulfate-Induced Colitis

References

• Saber S, Basuony M, Eldin AS. Telmisartan ameliorates dextran sodium sulfate-induced colitis in rats by modulating NF-κB signalling in the context of PPARγ agonistic activity. Arch Biochem Biophys. 2019;671:185–195. doi:10.1016/j.abb.2019.07.014
   PubMed Web of Science ®Google Scholar
• Saber S, El-Kader EMA. Novel complementary coloprotective effects of metformin and MCC950 by modulating HSP90/NLRP3 interaction and inducing autophagy in rats. Inflammopharmacology. 2021;29:237–251. doi:10.1007/s10787-020-00730-6
   PubMed Web of Science ®Google Scholar
• Saber S, Abd El-Kader EM, Sharaf H, et al. Celastrol augments sensitivity of NLRP3 to CP-456773 by modulating HSP-90 and inducing autophagy in dextran sodium sulphate-induced colitis in rats. Toxicol Appl Pharmacol. 2020;400:115075. doi:10.1016/j.taap.2020.115075
   PubMed Web of Science ®Google Scholar
• Figliuolo VR, Savio LEB, Safya H, et al. P2X7 receptor promotes intestinal inflammation in chemically induced colitis and triggers death of mucosal regulatory T cells. Biochim Biophys Acta Mol Basis Dis. 2017;1863(6):1183–1194. doi:10.1016/j.bbadis.2017.03.004
   PubMed Web of Science ®Google Scholar
• Marques CC, Castelo-Branco MT, Pacheco RG, et al. Prophylactic systemic P2X7 receptor blockade prevents experimental colitis. Biochim Biophys Acta Mol Basis Dis. 2014;1842(1):65–78. doi:10.1016/j.bbadis.2013.10.012
   Web of Science ®Google Scholar
• Di Virgilio F, Dal Ben D, Sarti AC, Giuliani AL, Falzoni S. The P2X7 receptor in infection and inflammation. Immunity. 2017;47(1):15–31. doi:10.1016/j.immuni.2017.06.020
   PubMed Web of Science ®Google Scholar
• Martínez-García JJ, Martínez-Banaclocha H, Angosto-Bazarra D, et al. P2X7 receptor induces mitochondrial failure in monocytes and compromises NLRP3 inflammasome activation during sepsis. Nat Commun. 2019;10(1):2711. doi:10.1038/s41467-019-10626-x
   PubMedGoogle Scholar
• Remy M, Thaler S, Schumann RG, et al. An in vivo evaluation of Brilliant Blue G in animals and humans. Br J Ophthalmol. 2008;92(8):1142. doi:10.1136/bjo.2008.138164
   PubMed Web of Science ®Google Scholar
• Peng W, Cotrina ML, Han X, et al. Systemic administration of an antagonist of the ATP-sensitive receptor P2X7 improves recovery after spinal cord injury. Proc Natl Acad Sci. 2009;106(30):12489. doi:10.1073/pnas.0902531106
   PubMed Web of Science ®Google Scholar
• Zhang X, Zhang M, Laties AM, Mitchell CH. Stimulation of P2X7 receptors elevates Ca2+ and kills retinal ganglion cells. Invest Ophthalmol Vis Sci. 2005;46(6):2183–2191. doi:10.1167/iovs.05-0052
   PubMed Web of Science ®Google Scholar
• Suzuki T, Hide I, Ido K, Kohsaka S, Inoue K, Nakata Y. Production and release of neuroprotective tumor necrosis factor by P2X7 receptor-activated microglia. J Neurosci. 2004;24(1):1. doi:10.1523/JNEUROSCI.3792-03.2004
   PubMed Web of Science ®Google Scholar
• Jacques-Silva MC, Rodnight R, Lenz G, et al. P2X7 receptors stimulate AKT phosphorylation in astrocytes. Br J Pharmacol. 2004;141(7):1106–1117. doi:10.1038/sj.bjp.0705685
   PubMed Web of Science ®Google Scholar
• Pereira JMS, Barreira AL, Gomes CR, et al. Brilliant blue G, a P2X7 receptor antagonist, attenuates early phase of renal inflammation, interstitial fibrosis and is associated with renal cell proliferation in ureteral obstruction in rats. BMC Nephrol. 2020;21(1):206. doi:10.1186/s12882-020-01861-2
   PubMed Web of Science ®Google Scholar
• Boucher D, Monteleone M, Coll RC, et al. Caspase-1 self-cleavage is an intrinsic mechanism to terminate inflammasome activity. J Exp Med. 2018;215(3):827–840. doi:10.1084/jem.20172222
   PubMed Web of Science ®Google Scholar
• Elliott EI, Sutterwala FS. Initiation and perpetuation of NLRP 3 inflammasome activation and assembly. Immunol Rev. 2015;265(1):35–52. doi:10.1111/imr.12286
   PubMed Web of Science ®Google Scholar
• Saber S, Khodir AE, Soliman WE, et al. Telmisartan attenuates N-nitrosodiethylamine-induced hepatocellular carcinoma in mice by modulating the NF-κB-TAK1-ERK1/2 axis in the context of PPARγ agonistic activity. Naunyn Schmiedebergs Arch Pharmacol. 2019;392(12):1591–1604. doi:10.1007/s00210-019-01706-2
   PubMed Web of Science ®Google Scholar
• Saber S, Ghanim AMH, El-Ahwany E, El-Kader EMA. Novel complementary antitumour effects of celastrol and metformin by targeting IκBκB, apoptosis and NLRP3 inflammasome activation in diethylnitrosamine-induced murine hepatocarcinogenesis. Cancer Chemother Pharmacol. 2020;85(2):331–343. doi:10.1007/s00280-020-04033-z
   PubMed Web of Science ®Google Scholar
• Perera AP, Fernando R, Shinde T, et al. MCC950, a specific small molecule inhibitor of NLRP3 inflammasome attenuates colonic inflammation in spontaneous colitis mice. Sci Rep. 2018;8(1):8618. doi:10.1038/s41598-018-26775-w
   PubMed Web of Science ®Google Scholar
• Tapia-Abellán A, Angosto-Bazarra D, Martínez-Banaclocha H, et al. MCC950 closes the active conformation of NLRP3 to an inactive state. Nat Chem Biol. 2019;15(6):560–564. doi:10.1038/s41589-019-0278-6
   PubMed Web of Science ®Google Scholar
• Jagtap A, Shirke S, Phadke A. Effect of polyherbal formulation on experimental models of inflammatory bowel diseases. J Ethnopharmacol. 2004;90(2–3):195–204. doi:10.1016/j.jep.2003.09.042
   PubMed Web of Science ®Google Scholar
• Khalil R, Shata A, Abd El-Kader EM, et al. Vildagliptin, a DPP-4 inhibitor, attenuates carbon tetrachloride-induced liver fibrosis by targeting ERK1/2, p38α, and NF-κB signaling. Toxicol Appl Pharmacol. 2020;407:115246. doi:10.1016/j.taap.2020.115246
   PubMed Web of Science ®Google Scholar
• Younis NS, Ghanim AMH, Saber S. Mebendazole augments sensitivity to sorafenib by targeting MAPK and BCL-2 signalling in n-nitrosodiethylamine-induced murine hepatocellular carcinoma. Sci Rep. 2019;9(1):19095. doi:10.1038/s41598-019-55666-x
   PubMedGoogle Scholar
• Franchi L, Eigenbrod T, Muñoz-Planillo R, Nuñez G. The inflammasome: a caspase-1-activation platform that regulates immune responses and disease pathogenesis. Nat Immunol. 2009;10(3):241–247. doi:10.1038/ni.1703
   PubMed Web of Science ®Google Scholar
• Coll RC, Robertson AAB, Chae JJ, et al. A small-molecule inhibitor of the NLRP3 inflammasome for the treatment of inflammatory diseases. Nat Med. 2015;21(3):248–255. doi:10.1038/nm.3806
   PubMed Web of Science ®Google Scholar
• Dinarello CA, van der Meer JWM. Treating inflammation by blocking interleukin-1 in humans. Semin Immunol. 2013;25(6):469–484.
   PubMed Web of Science ®Google Scholar
• Liu Y, Xiao Y, Li Z. P2X7 receptor positively regulates MyD88-dependent NF-κB activation. Cytokine. 2011;55(2):229–236. doi:10.1016/j.cyto.2011.05.003
   PubMed Web of Science ®Google Scholar
• Ma Y, Jiang J, Gao Y, et al. Research progress of the relationship between pyroptosis and disease. Am J Transl Res. 2018;10(7):2213–2219.
   PubMed Web of Science ®Google Scholar
• Saber S, Abd El-Fattah EE, Yahya G, et al. A novel combination therapy using rosuvastatin and lactobacillus combats dextran sodium sulfate-induced colitis in high-fat diet-fed rats by targeting the TXNIP/NLRP3 interaction and influencing gut microbiome composition. Pharmaceuticals. 2021;14(4):341. doi:10.3390/ph14040341
   Web of Science ®Google Scholar
• Mao L, Kitani A, Strober W, Fuss IJ. The role of NLRP3 and IL-1β in the pathogenesis of inflammatory bowel disease. Front Immunol. 2018;9:2566.
   PubMed Web of Science ®Google Scholar
• Pizarro TT, Michie MH, Bentz M, et al. IL-18, a novel immunoregulatory cytokine, is up-regulated in Crohn’s disease: expression and localization in intestinal mucosal cells. J Immunol. 1999;162(11):6829.
   PubMed Web of Science ®Google Scholar
• van Hemert S, Meijerink M, Molenaar D, et al. Identification of Lactobacillus plantarum genes modulating the cytokine response of human peripheral blood mononuclear cells. BMC Microbiol. 2010;10:293. doi:10.1186/1471-2180-10-293
   PubMed Web of Science ®Google Scholar
• Bien E, Balcerska A, Adamkiewicz-Drozynska E, Rapala M, Krawczyk M, Stepinski J. Pre-treatment serum levels of interleukin-10, interleukin-12 and their ratio predict response to therapy and probability of event-free and overall survival in childhood soft tissue sarcomas, Hodgkin’s lymphomas and acute lymphoblastic leukemias. Clin Biochem. 2009;42(10–11):1144–1157. doi:10.1016/j.clinbiochem.2009.04.004
   PubMed Web of Science ®Google Scholar
• Abdel-Ghany R, Rabia I, El-Ahwany E, et al. Blockade of PGE2, PGD2 receptors confers protection against prepatent schistosomiasis mansoni in mice. J Egypt Soc Parasitol. 2015;45(3):511–520. doi:10.12816/0017911
   PubMedGoogle Scholar
• López-Castejón G, Pelegrín P. Current status of inflammasome blockers as anti-inflammatory drugs. Expert Opin Investig Drugs. 2012;21(7):995–1007. doi:10.1517/13543784.2012.690032
   PubMed Web of Science ®Google Scholar